Holocene Advisors LP Has $49.50 Million Position in STERIS plc $STE

Holocene Advisors LP boosted its holdings in STERIS plc (NYSE:STE) by 977.7% during the third quarter, Holdings Channel reports. The fund owned 200,045 shares of the medical equipment provider’s stock after purchasing an additional 181,482 shares during the period. Holocene Advisors LP’s holdings in STERIS were worth $49,499,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in STE. Gotham Asset Management LLC boosted its position in STERIS by 26.2% during the third quarter. Gotham Asset Management LLC now owns 163,857 shares of the medical equipment provider’s stock worth $40,545,000 after purchasing an additional 34,003 shares during the period. Focus Partners Wealth raised its position in shares of STERIS by 51.4% in the third quarter. Focus Partners Wealth now owns 13,137 shares of the medical equipment provider’s stock valued at $3,250,000 after purchasing an additional 4,461 shares during the period. Capula Management Ltd bought a new position in shares of STERIS in the third quarter valued at about $2,012,000. Chevy Chase Trust Holdings LLC lifted its stake in shares of STERIS by 2.6% during the 3rd quarter. Chevy Chase Trust Holdings LLC now owns 54,264 shares of the medical equipment provider’s stock worth $13,427,000 after buying an additional 1,368 shares during the last quarter. Finally, California Public Employees Retirement System lifted its stake in shares of STERIS by 3.2% during the 3rd quarter. California Public Employees Retirement System now owns 171,998 shares of the medical equipment provider’s stock worth $42,559,000 after buying an additional 5,393 shares during the last quarter. Institutional investors and hedge funds own 94.69% of the company’s stock.

STERIS Stock Up 2.1%

STE stock opened at $219.18 on Tuesday. STERIS plc has a fifty-two week low of $204.90 and a fifty-two week high of $269.44. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.48 and a quick ratio of 1.75. The stock has a market capitalization of $21.49 billion, a price-to-earnings ratio of 30.57 and a beta of 1.05. The business’s fifty day moving average price is $250.22 and its two-hundred day moving average price is $250.34.

STERIS (NYSE:STE) last announced its earnings results on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $2.53. STERIS had a net margin of 12.15% and a return on equity of 14.34%. During the same period in the previous year, the firm earned $2.32 earnings per share. The business’s revenue for the quarter was up 9.2% on a year-over-year basis. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. On average, equities analysts anticipate that STERIS plc will post 9.08 earnings per share for the current year.

STERIS Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 19th. Shareholders of record on Tuesday, February 17th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Tuesday, February 17th. This represents a $2.52 dividend on an annualized basis and a yield of 1.1%. STERIS’s payout ratio is currently 35.15%.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Weiss Ratings reiterated a “buy (b)” rating on shares of STERIS in a research note on Friday, January 9th. Wall Street Zen upgraded shares of STERIS from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 7th. Six equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $275.20.

Insider Activity

In other STERIS news, Director Cynthia L. Feldmann sold 3,098 shares of the stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $237.21, for a total transaction of $734,876.58. Following the transaction, the director owned 705 shares in the company, valued at $167,233.05. This represents a 81.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.07% of the stock is currently owned by insiders.

STERIS Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.